NH - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.3
| Stock Code | NH | Market Cap | 36,051 Cr. | Current Price | 1,762 ₹ | High / Low | 2,372 ₹ |
| Stock P/E | 73.0 | Book Value | 114 ₹ | Dividend Yield | 0.26 % | ROCE | 19.4 % |
| ROE | 21.0 % | Face Value | 10.0 ₹ | DMA 50 | 1,760 ₹ | DMA 200 | 1,769 ₹ |
| Chg in FII Hold | -1.12 % | Chg in DII Hold | 1.23 % | PAT Qtr | 109 Cr. | PAT Prev Qtr | 138 Cr. |
| RSI | 50.9 | MACD | 14.0 | Volume | 5,89,619 | Avg Vol 1Wk | 3,05,344 |
| Low price | 1,564 ₹ | High price | 2,372 ₹ | PEG Ratio | 1.58 | Debt to equity | 0.69 |
| 52w Index | 24.5 % | Qtr Profit Var | 37.1 % | EPS | 22.6 ₹ | Industry PE | 48.0 |
📊 NH shows moderate fundamentals with ROE (21.0%) and ROCE (19.4%), supported by manageable debt-to-equity (0.69). However, the stock trades at a premium valuation (P/E 73 vs industry 48), making it expensive relative to peers. EPS of 22.6 ₹ is decent, but dividend yield is low (0.26%). Quarterly profit declined (109 Cr vs 138 Cr), raising short-term concerns. Technicals show neutral momentum (RSI 50.9, MACD 14.0) with price hovering around DMA levels (50 DMA: 1,760 ₹, 200 DMA: 1,769 ₹).
💡 Entry Price Zone: Attractive accumulation range lies between 1,650 ₹ – 1,720 ₹, closer to DMA support levels, offering better risk-reward.
📈 Exit Strategy / Holding Period: If already holding, maintain a medium-term horizon (2–4 years) given efficiency metrics but stretched valuations. Consider partial profit booking near 2,200 ₹–2,300 ₹ resistance zone. Long-term investors should hold only if earnings growth stabilizes and valuations normalize.
✅ Positive
- Strong ROE (21.0%) and ROCE (19.4%) show efficient capital usage.
- EPS of 22.6 ₹ provides earnings visibility.
- DII holdings increased (+1.23%), showing domestic institutional support.
⚠️ Limitation
- High P/E (73) compared to industry average (48).
- Dividend yield of 0.26% is very low.
- Quarterly profit decline (109 Cr vs 138 Cr).
📉 Company Negative News
- FII holdings decreased (-1.12%), showing reduced foreign investor confidence.
- Quarterly profit decline raises concerns about earnings consistency.
📈 Company Positive News
- DII holdings increased (+1.23%), showing domestic support.
- Stock trading near DMA levels, indicating technical stability.
🏭 Industry
- Industry P/E at 48 suggests sector is moderately valued compared to NH.
- Healthcare sector benefits from rising demand but faces regulatory and cost pressures.
🔎 Conclusion
NH is fundamentally efficient with strong ROE/ROCE, but valuations are stretched and profitability has weakened. Fresh entry is attractive near 1,650 ₹–1,720 ₹. Existing holders should maintain positions with a 2–4 year horizon, booking profits near resistance levels while monitoring earnings stability and institutional investor sentiment.